Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has received a full explanation of the study drug and this study in advance, and written informed consent to participate in the study has been obtained from the subject himself/herself~* Outpatient has RA that was diagnosed according to the 1987 revised criteria of the ACR at least 6 months prior to screening~* At screening subject has active RA as evidenced by all of the following:~  * ≥ 6 tender/painful joints;~ * ≥ 6 swollen joints;~ * CRP of ≥ 0.5 mg/dL or ESR of ≥ 28 mm/h.C-Reactive Protein (CRP) of ≥ 0.8 mg/dL or Erythrocyte Sedimentation Rate (ESR) of ≥ 28 mm/hr~* Subject meets the ACR 1991 Revised Criteria for the Classification of Global Functional Status in RA, Class I, II or, III at screening~Exclusion Criteria:~* Positive tuberculin (TB) test within 90 days of Screening~* Abnormal chest x-ray indicative of an acute or chronic infectious process or malignancy~* Receipt of live or live attenuated virus vaccination within 30 days prior to the first dose of study drug~* Hepatitis B virus or hepatitis C virus carrier or has a history of a positive test for human immunodeficiency virus (HIV) infection~* Any other autoimmune rheumatic disease, other than Sjogren's syndrome~* Previous history of clinically significant infections or illness (requiring hospitalization or requiring parenteral therapy) within 90 days of the Screening visit, or a history of any illness that would preclude participation in the study~* History of any malignancy, except for successfully treated basal or squamous cell carcinoma of the skin or in-situ carcinoma of the cervix~* Does not meet specified washout criteria for the following RA medications: etanercept, certolizumab, adalimumab, golimumab, infliximab and tocilizumab, rituximab, abatacept, anakinra, methotrexate, sulfasalazine, hydroxychloroquine, gold, penicillamine or leflunomide~* Previous intolerance to Janus kinase (JAK) inhibitors~* Receipt of intra-articular or parenteral corticosteroid within 28 days prior to the first dose of study drug~* Receipt of plasma exchange therapy within 60 days prior to the start of study drug~* Receipt of any investigational agent within 30 days or 5 half-lives, whichever is longer, prior to first dose of study drug~* Receipt of medications that are CYP3A substrates with narrow therapeutic range within 14 days prior to first dose of study drug~* History of heart failure, defined as New York Heart Association (NYHA) grade 3 or greater

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ASP015K lowest dose (Type: EXPERIMENTAL): Oral
- ASP015K low dose (Type: EXPERIMENTAL): Oral
- ASP015K medium dose (Type: EXPERIMENTAL): Oral
- ASP015K high dose (Type: EXPERIMENTAL): Oral
- Placebo (Type: PLACEBO_COMPARATOR): Oral

Based on this trial design, predict the completion outcome and termination type (if applicable).